ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Esophageal Cancer
Prostatic Cancer

Adenocarcinoma trials near New Haven, CT, USA:

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma...

Enrolling
Advanced Adenocarcinoma
Drug: BA3182

Phase 1

BioAtla

New Haven, Connecticut, United States and 4 other locations

and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatme...

Enrolling
Adenocarcinoma of Lung
Device: NovoTTF-200T System

Phase 1

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 6 other locations

The purpose of this study is to evaluate the good and bad effects when regorafenib is used instead of standard combination chemotherapy. It is not kn...

Active, not recruiting
Metastatic Colorectal Adenocarcinoma
Drug: Regorafenib

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 6 other locations

with locally advanced or borderline resectable pancreatic ductal adenocarcinoma (PDAC) before surgery. This type of treatment approach is ca...

Enrolling
Pancreatic Ductal Adenocarcinoma
Drug: NALIRIFOX
Combination Product: AD-XRT and Capecitabine

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 6 other locations

The purpose of this study is to test any good and bad effects of the study drug called PEGPH20. PEGPH20 alone is considered investigational. The Food...

Active, not recruiting
Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer
Drug: Nab-paclitaxel
Drug: Gemcitabine
Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Hartford, Connecticut, United States and 9 other locations

and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastric Cancer
Drug: AZD0901
Drug: Capecitabine

Phase 2

AstraZeneca
AstraZeneca

Shirley, New York, United States and 42 other locations

combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).Two cohorts will be enrolled in parallel in this study:...

Active, not recruiting
Pancreatic Adenocarcinoma
Drug: Gemcitabine
Drug: Bevacizumab

Phase 1, Phase 2

Roche
Roche

New Haven, Connecticut, United States and 26 other locations

mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer tre...

Enrolling
Adenocarcinoma, Pancreatic Ductal
Drug: mFOLFIRINOX
Drug: Autogene cevumeran

Phase 2

Genentech
Genentech

New Haven, Connecticut, United States and 44 other locations

participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...

Enrolling
Endometrial Adenocarcinoma
Urothelial Carcinoma
Diagnostic Test: OncoSignature
Drug: ACR-368

Phase 1, Phase 2

Acrivon Therapeutics

New Haven, Connecticut, United States and 66 other locations

The study researchers think that combining the drugs pembrolizumab and olaparib (POLAR) may help people with this disease because pembrolizumab activ...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Homologous Recombination Deficiency (HRD)
Drug: Olaparib
Drug: Pembrolizumab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Commack, New York, United States and 6 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems